Q2
CADL — Q2 2026 Financial Report Analysis
Candel's Q2 2026 net loss widened to $38.9M as aglatimagene trial, manufacturing and launch-prep spending more than doubled operating costs to $26.7M, with $201.6M in cash ahead of a planned Q4 2026 prostate cancer BLA.